Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ: JAZZ )

124.00 +0.27 (+0.22%)
Streaming Delayed Price Updated: 11:18 AM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
10 Small And Mid-Cap Growth Stocks To Buy Today
If you are looking for long-term growth, you will most likely find it in small and mid-cap stocks because they have the room to grow. The bigger a company gets, the more difficult it is to achieve... 
Via Talk Markets
This Cannabis Stock Is Full of Potential and Hasn't Been This Cheap in Months
Investors have been selling off the stock since the company released its earnings report earlier this month. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
10 Biggest Price Target Changes For Monday
UBS boosted the price target on Seagate Technology Holdings plc (NASDAQ: 
Via Benzinga
The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Where Jazz Pharmaceuticals Stands With Analysts
Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ... 
Via Benzinga
The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small-... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
GW Pharmaceuticals' Cannabidiol For Seizures Wins UK Approval
The U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has approved GW Pharmaceuticals' cannabidiol as an adjunctive treatment of seizures... 
Via Benzinga
Watch Medical Marijuana & Unrivaled Brands At The Benzinga Cannabis Hour
Benzinga’s Cannabis Hour is a live show for cannabis investors. On Thursday's show, hosts ... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Daily Podcast 8/5: Europe Expansion And Buy The Dip Opportunity Stocks
Start The Day With The Best Daily Pre-Market Overview Of The Can... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
Innovators in Pharma Sectors See Potential, Promise in Providing Improved Treatments
Via FinancialNewsMedia
Jazz Pharmaceuticals PLC (JAZZ) Q2 2021 Earnings Call Transcript
JAZZ earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Jazz Pharmaceuticals Q2 Earnings
Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 5.12% over the past... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi... 
Via Benzinga
Jazz Pharmaceuticals's Earnings: A Preview
Jazz Pharmaceuticals (NASDAQ:JAZZ) releases its next round of earnings this Tuesday, August 03. Get the latest predictions in Benzinga's essential guide to the company's Q2... 
Via Benzinga
Does Big Business Provide A Better Look Into Cannabis Reform Than Capitol Hill? Operators Believe So.
Cannabis operators and executives tell Benzinga that the movement of private and public companies may serve as a better indicator of regula... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Is Jazz Pharmaceuticals Stock a Buy?
Jazz Pharma is not the most popular drugmaker, but it is definitely worth a second look. 
Via The Motley Fool
The Week In Cannabis: Justice Clarence Thomas, Mexico's Decriminalization, Apple's Policy Changes, Tilray And More
Below is a recap of the main news related to the cannabis industry and markets for the week of June 28, 2021. Justice Thomas&nbs... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Global Cannabis Stocks Decline 8.7% in Q2, Agrify, KushCo Among Strongest Cannabis Names In June
The Global Cannabis Stock Index fell for the fourth straight month, dropping 4.1% to 57.10. During the second quarter, the index was down... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE... 
Via Benzinga
Exposures Product Safety
Jazz Pharma's Rylaze Scores FDA Approval For Blood Cancer
The FDA has approved Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the treatment of acute lymphoblastic... 
Via Benzinga
Exposures Product Safety
Got $5,000? These 3 Stocks Are Ridiculously Cheap Buys
They are great options whether you are investing for the short or long term. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
Finding Value In Mid-Cap Stocks
Within the mid-cap space there is something for everyone. 
Via Talk Markets
New Cannabinoid-Based Drug Candidates from Artelo Biosciences Show Promise as Cancer and Mental Health Treatments; Key Data Due Before Year End
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or... 
Via Benzinga
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Goldman Sachs lowered Casey's General Stores, Inc. (NASDAQ: 
Via Benzinga
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away... 
Via Benzinga
10 Biggest Price Target Changes For Monday
SVB Leerink raised Natera, Inc. (NASDAQ:NTRA) pr... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.